Addendum
Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55
Report documents
-
Addendum
Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55
Dossier assessment
Indication:
Adults with HIV-1 infection whose virus has no known or suspected resistance to integrase inhibitors or lamivudine
Result of dossier assessment:
Now proof of considerable (before: minor) added benefit for treatment-naive adults with HIV-1 infection
Additional information
Federal Joint Committee (G-BA)
2020-02-06 A G-BA decision was published.
Project details
- Project no.
- A19-102
- Commission
- Commission awarded on 09.12.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Addendum
Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55
Status: Commission completed
-
Dossier assessment
Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed